Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

Bearman, 1995, The syndrome of hepatic veno-occlusive disease after marrow transplantation, Blood, 85, 3005, 10.1182/blood.V85.11.3005.bloodjournal85113005 Carreras, 1998, Blood, 92, 3599 Richardson, 1999, The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches, Br J Haematol, 107, 485, 10.1046/j.1365-2141.1999.01680.x McDonald, 1984, Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors, Hepatology, 4, 116, 10.1002/hep.1840040121 McDonald, 1993, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, 118, 255, 10.7326/0003-4819-118-4-199302150-00003 Jones, 1987, Veno-occlusive disease of the liver following bone marrow transplantation, Transplantation, 44, 778, 10.1097/00007890-198712000-00011 Bearman, 1993, Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation, J Clin Oncol, 11, 1729, 10.1200/JCO.1993.11.9.1729 Shulman, 1987, Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules, Am J Pathol, 127, 549 Shulman, 1994, Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms, Hepatology, 19, 1171, 10.1002/hep.1840190515 Kumar, 2003, Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation, Mayo Clin Proc, 78, 589, 10.4065/78.5.589 Bearman, 2001, Avoiding hepatic veno-occlusive disease: what do we know and where are we going?, Bone Marrow Transplant, 27, 1113, 10.1038/sj.bmt.1703014 Coppell, 2003, Veno-occlusive disease: cytokines, genetics, and haemostasis, Blood Rev, 17, 63, 10.1016/S0268-960X(03)00002-X Jacobs, 1979, Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia, S Afr Med J, 55, 5 Berk, 1979, Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease, Ann Intern Med, 90, 158, 10.7326/0003-4819-90-2-158 Wadleigh, 2003, Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment, Curr Opin Hematol, 10, 451, 10.1097/00062752-200311000-00010 Reiss, 2002, Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients, J Pediatr Hematol Oncol, 24, 746, 10.1097/00043426-200212000-00013 Vogelsang, 2002, Hepatic veno-occlusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome, J Pediatr Hematol Oncol, 24, 706, 10.1097/00043426-200212000-00004 Chalandon, 2004, Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 10, 347, 10.1016/j.bbmt.2004.01.002 Richardson, 2007, Blood, 110, 614, 10.1182/blood-2006-08-036947 Richardson, 2006, Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post-SCT: final results of a multi-center, randomized, dose-finding trial. ASH Annual Meeting Abstracts, Blood, 108, 43, 10.1182/blood.V108.11.43.43 Attal, 1992, Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial, Blood, 79, 2834, 10.1182/blood.V79.11.2834.bloodjournal79112834 Rosenthal, 1996, Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation, Bone Marrow Transplant, 18, 185 Simon, 2001, Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin, Bone Marrow Transplant, 27, 627, 10.1038/sj.bmt.1702854 Ohashi, 2000, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation, Am J Hematol, 64, 32, 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N Essell, 1992, Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients, Bone Marrow Transplant, 10, 367 Marsa-Vila, 1991, Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation, Eur J Haematol, 47, 346, 10.1111/j.1600-0609.1991.tb01859.x Hagglund, 1997, Risk factors for hepatic veno-occlusive disease in 500 allogeneic bone marrow transplant recipients, Bone Marrow Transplant, 19, S17 Park, 1997, Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation, Bone Marrow Transplant, 19, 915, 10.1038/sj.bmt.1700760 Hagglund, 1998, Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation, Blood, 92, 4568, 10.1182/blood.V92.12.4568 Ruutu, 2002, Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation, Blood, 100, 1977, 10.1182/blood-2001-12-0159 Gardner, 1989 Armitage, 1987 Copelan, 2000, The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy, Bone Marrow Transplant, 26, 1037, 10.1038/sj.bmt.1702689 Lee, 2002, Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide, Br J Haematol, 118, 1087, 10.1046/j.1365-2141.2002.03748.x Lee, 1999, Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation, Bone Marrow Transplant, 24, 591, 10.1038/sj.bmt.1701955 Radich, 1993, Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total body irradiation–containing regimens, J Clin Oncol, 11, 304, 10.1200/JCO.1993.11.2.304 Lapierre, 2005, Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children, Transplantation, 80, 314, 10.1097/01.tp.0000167758.63247.f4 Bouligand, 2007, Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors, Clin Pharmacol Ther, 82, 402, 10.1038/sj.clpt.6100168 Horn, 2002, Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma, Bone Marrow Transplant, 29, 409, 10.1038/sj.bmt.1703393 Lee, 1999, Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome, Biol Blood Marrow Transplant, 5, 306, 10.1016/S1083-8791(99)70006-6 Meresse, 1992, Risk factors for hepatic veno-occlusive disease after high-dose busulfan–containing regimens followed by autologous bone marrow transplantation: a study in 136 children, Bone Marrow Transplant, 10, 135 Baxter-Lowe, 1994, Molecular techniques for typing unrelated marrow donors: potential impact of molecular typing disparity on donor selection, Bone Marrow Transplant, 14, S42 Crilley, 1995, Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation, Bone Marrow Transplant, 15, 361 Nemunaitis, 1995, Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation, Bone Marrow Transplant, 15, 949 Holland, 1996, Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem cell transplantation and comprehensive supportive care, J Clin Oncol, 14, 1156, 10.1200/JCO.1996.14.4.1156 Vassal, 1996, Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation, Cancer Chemother Pharmacol, 37, 247, 10.1007/BF00688324 Carreras, 1998, Veno-occlusive disease of the liver after allogeneic blood and marrow transplantation: a retrospective analysis of 376 consecutive BMT performed at a single centre, Bone Marrow Transplant, 21, S239 Jillella, 1999, Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia, Bone Marrow Transplant, 23, 1095, 10.1038/sj.bmt.1701786 Rocha, 2001, Plasma levels of t-PA Ag and D-dimer predict development of veno-occlusive disease of the liver (VOD) in patients undergoing allogeneic stem cell transplant, Blood, 98, 3541 Parikh, 2002, Renal dysfunction in allogeneic hematopoietic cell transplantation, Kidney Int, 62, 566, 10.1046/j.1523-1755.2002.00455.x Schetelig, 2002, Allogeneic transplantation after reduced conditioning in high-risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease, Haematologica, 87, 299 Einsele, 2003, A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma, Bone Marrow Transplant, 32, 593, 10.1038/sj.bmt.1704192 Hahn, 2003, Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients, Bone Marrow Transplant, 32, 405, 10.1038/sj.bmt.1704144 de Lima, 2004, Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS, Blood, 104, 857, 10.1182/blood-2004-02-0414 Srivastava, 2004, Glutathione S-transferase M1 polymorphism: a risk factor for hepatic veno-occlusive disease in bone marrow transplantation, Blood, 104, 1574, 10.1182/blood-2003-11-3778 Styler, 1996, Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis, Bone Marrow Transplant, 18, 171 Hasegawa, 1998, Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors, Bone Marrow Transplant, 22, 1191, 10.1038/sj.bmt.1701506 Sullivan, 1998, Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation, Biol Blood Marrow Transplant, 4, 20, 10.1016/S1083-8791(98)90006-4 Locasciulli, 1999, The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group, Transplantation, 68, 1486, 10.1097/00007890-199911270-00010 Copelan, 2000, Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma, Bone Marrow Transplant, 25, 1243, 10.1038/sj.bmt.1702433 Tomas, 2000, Plasma endothelin-1 levels after stem cell transplantation, Bone Marrow Transplant, 26, 1199, 10.1038/sj.bmt.1702691 Moscardo, 2001, Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection, Bone Marrow Transplant, 27, 983, 10.1038/sj.bmt.1703025 Park, 2002, A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation, Bone Marrow Transplant, 29, 137, 10.1038/sj.bmt.1703342 McDonald, 2003, Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation, Blood, 101, 2043, 10.1182/blood-2002-06-1860 Moscardo, 2003, Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation, Exp Hematol, 31, 545, 10.1016/S0301-472X(03)00070-5 Kalayoglu-Besisik, 2005, Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years, Transplant Proc, 37, 2285, 10.1016/j.transproceed.2005.03.025 Cesaro, 2005, A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation, Haematologica, 90, 1396 Lee, 2005, Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation, Ann Hematol, 84, 321, 10.1007/s00277-004-0982-4 Sartori, 2005, Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population, Thromb Hemost, 93, 682, 10.1160/TH04-09-0621 Batsis, 2006, Veno-occlusive disease prophylaxis with fresh-frozen plasma and heparin in bone marrow transplantation, Thromb Res, 118, 611, 10.1016/j.thromres.2005.10.010 Wadleigh, 2003, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation, Blood, 102, 1578, 10.1182/blood-2003-01-0255 Kashyap, 2002, Biol Blood Marrow Transplant, 8, 493, 10.1053/bbmt.2002.v8.pm12374454 Litzow, 2002, Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator, Leuk Lymphoma, 43, 2099, 10.1080/1042819021000032962 Bajwa, 2003, Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment, Bone Marrow Transplant, 31, 591, 10.1038/sj.bmt.1703881 Sucak, 2007, Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience, Transplant Proc, 39, 1558, 10.1016/j.transproceed.2007.01.075 Haussmann, 2006, Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy, Haematologica, 91, 795 Richardson, 2002, Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome, Blood, 100, 4337, 10.1182/blood-2002-04-1216 Song, 2006, Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children, J Korean Med Sci, 21, 897, 10.3346/jkms.2006.21.5.897 Brice, 2007, Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics, Pharmacoepidemiol Drug Saf, 17, 135 Cheuk, 2007, Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation, Bone Marrow Transplant, 40, 935, 10.1038/sj.bmt.1705835 Blostein, 1992, A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation, Bone Marrow Transplant, 10, 439 Andersson, 2002, Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study, Biol Blood Marrow Transplant, 8, 145, 10.1053/bbmt.2002.v8.pm11939604 Barker, 2005, GI complications in pediatric patients post-BMT, Bone Marrow Transplant, 36, 51, 10.1038/sj.bmt.1705004 Barker, 2003, Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 32, 79, 10.1038/sj.bmt.1704069 Richardson, 2004, Defibrotide (DF) for the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post-SCT: final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings, Blood, 104 Richardson, 2005, Defibrotide (DF) for the treatment of veno-occlusive disease (VOD) and multi-system organ failure (MOF) post-SCT: analysis of response and survival according to degree and type of MOF, Blood, 106, 399, 10.1182/blood.V106.11.399.399 Strasser, 1999, Gastrointestinal and hepatic complications, 627 Aversa, 2002, Haploidentical stem cell transplantation for acute leukemia, Int J Hematol, 76, 165, 10.1007/BF03165238 Olavarria, 2000, High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience, Br J Haematol, 108, 769, 10.1046/j.1365-2141.2000.01905.x Russell, 2002, Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes, Biol Blood Marrow Transplant, 8, 468, 10.1053/bbmt.2002.v8.pm12374451 Ramasamy, 2006, Incidence and management of hepatic veno-occlusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT), Bone Marrow Transplant, 38, 823, 10.1038/sj.bmt.1705528 Olavarria, 2000, A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation, Leukemia, 14, 1954, 10.1038/sj.leu.2401921 Clopes, 2006, Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage, Eur J Haematol, 77, 1, 10.1111/j.0902-4441.2006.t01-1-EJH2478.x Spitzer, 2008, Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus–associated lymphoma: AIDS Malignancy Consortium study 020, Biol Blood Marrow Transplant, 14, 59, 10.1016/j.bbmt.2007.03.014 Soiffer, 1991, Hepatic dysfunction following T-cell–depleted allogeneic bone marrow transplantation, Transplantation, 52, 1014, 10.1097/00007890-199112000-00015 Girinsky, 2000, Prospective randomized comparison of single-dose versus hyperfractionated total body irradiation in patients with hematologic malignancies, J Clin Oncol, 18, 981, 10.1200/JCO.2000.18.5.981 Cosset, 1989, Single-dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy, Radiother Oncol, 15, 151, 10.1016/0167-8140(89)90129-1 Locasciulli, 1989, Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation, Transplantation, 48, 68, 10.1097/00007890-198907000-00016 Ayash, 1990, Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas, J Clin Oncol, 8, 1699, 10.1200/JCO.1990.8.10.1699 Resbeut, 1990, Results of fractionated TBI prior to bone marrow transplantation in standard-risk leukaemia at Marseille, Radiother Oncol, 18, 132, 10.1016/0167-8140(90)90193-Z Atkinson, 1987, Preparative regimens for marrow transplantation containing busulfan are associated with hemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis, Bone Marrow Transplant, 2, 385 Holler, 1990, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation, Blood, 75, 1011, 10.1182/blood.V75.4.1011.1011 Morgan, 1991, The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation, Br J Haematol, 77, 529, 10.1111/j.1365-2141.1991.tb08621.x Petersdorf, 2004, HLA matching in allogeneic stem cell transplantation, Curr Opin Hematol, 11, 386, 10.1097/01.moh.0000143701.88042.d9 Bartelink, 2008, Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 14, 88, 10.1016/j.bbmt.2007.09.015 Nabhan, 2001, The role of bone marrow transplantation in acute promyelocytic leukemia, Bone Marrow Transplant, 28, 219, 10.1038/sj.bmt.1703119 Goldman, 2003, Clinical decisions for chronic myeloid leukemia in the imatinib era, Semin Hematol, 40, 98, 10.1053/shem.2003.50049 Cutler, 2008, Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation, Blood, 112, 4425, 10.1182/blood-2008-07-169342 Platzbecker, 2009, Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial, Biol Blood Marrow Transplant, 15, 101, 10.1016/j.bbmt.2008.11.004 Richardson, 2001, Hepatic veno-occlusive disease following hematopoietic stem cell transplantation, Acta Haematol, 106, 57, 10.1159/000046590 Mahmoud, 1996, Schistosomiasis as a predisposing factor to veno-occlusive disease of the liver following allogeneic bone marrow transplantation, Bone Marrow Transplant, 17, 401 Bearman, 1997, Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients, Blood, 89, 1501, 10.1182/blood.V89.5.1501 Chopra, 2000, Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study, Br J Haematol, 111, 1122, 10.1046/j.1365-2141.2000.02475.x Brugieres, 1988, Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome, Bone Marrow Transplant, 3, 53 Richardson, 1998, Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population, Blood, 92, 737 Corbacioglu, 2004, Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicenter study demonstrates therapeutic efficacy upon early intervention, Bone Marrow Transplant, 33, 189, 10.1038/sj.bmt.1704329 Gordon, 1998, Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation, Bone Marrow Transplant, 22, 999, 10.1038/sj.bmt.1701464 Haire, 2002, Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation, Crit Care Med, 30, S257, 10.1097/00003246-200205001-00014 Haire, 1999, The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation, Semin Thromb Hemost, 25, 223, 10.1055/s-2007-994924 Haire, 1995, Multiple organ dysfunction syndrome in bone marrow transplantation, JAMA, 274, 1289, 10.1001/jama.1995.03530160041031 Khassawneh, 2002, Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation, Chest, 121, 185, 10.1378/chest.121.1.185 Diaz de Heredia, 1999, Role of the intensive care unit in children undergoing bone marrow transplantation with life-threatening complications, Bone Marrow Transplant, 24, 163, 10.1038/sj.bmt.1701874 Rossi, 1999, Prognosis of pediatric bone marrow transplant recipients requiring mechanical ventilation, Crit Care Med, 27, 1181, 10.1097/00003246-199906000-00048 Haire, 1998, A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 4, 142, 10.1016/S1083-8791(98)50003-1 Morris, 1997, Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation, Bone Marrow Transplant, 20, 871, 10.1038/sj.bmt.1700985 Rubenfeld, 1996, Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines, Ann Intern Med, 125, 625, 10.7326/0003-4819-125-8-199610150-00001 Afessa, 1992, Outcome of recipients of bone marrow transplants who require intensive care unit support, Mayo Clin Proc, 67, 117, 10.1016/S0025-6196(12)61310-X Letourneau, 2002, Acute renal failure in bone marrow transplant patients admitted to the intensive care unit, Nephron, 90, 408, 10.1159/000054728 Keenan, 2000, Outcome of children who require mechanical ventilatory support after bone marrow transplantation, Crit Care Med, 28, 830, 10.1097/00003246-200003000-00036 Zager, 1989, Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients, Am J Kidney Dis, 13, 210, 10.1016/S0272-6386(89)80054-X Lane, 1994, Outcome of dialysis for acute renal failure in pediatric bone marrow transplant patients, Bone Marrow Transplant, 13, 613 Kist-van Holthe, 1998, Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT, Bone Marrow Transplant, 22, 559, 10.1038/sj.bmt.1701388 Gruss, 1995, Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome, Am J Nephrol, 15, 473, 10.1159/000168889 Wingard, 1989, Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients, Bone Marrow Transplant, 4, 685 Merouani, 1996, Renal function in high-dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer, Kidney Int, 50, 1026, 10.1038/ki.1996.405 Kist-van Holthe, 2002, Prospective study of renal insufficiency after bone marrow transplantation, Pediatr Nephrol, 17, 1032, 10.1007/s00467-002-0989-9 Torrecilla, 1988, Prognostic assessment of the acute complications of bone marrow transplantation requiring intensive therapy, Intens Care Med, 14, 393, 10.1007/BF00262895 Todd, 1994, Survival outcome among 54 intubated pediatric bone marrow transplant patients, Crit Care Med, 22, 171, 10.1097/00003246-199401000-00030 Jacobe, 2003, Outcome of children requiring admission to an intensive care unit after bone marrow transplantation, Crit Care Med, 31, 1299, 10.1097/01.CCM.0000060011.88230.C8 McDonald, 1991, Liver toxicity following cytoreductive therapy for marrow transplantation: risk factors, incidence and outcome, Hepatology, 14, 162A Klaesson, 1995, Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?, Transplantation, 60, 1225, 10.1097/00007890-199512000-00009 Gooley, 2005, Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation, Hepatology, 41, 345, 10.1002/hep.20529